Edition:
United Kingdom

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

12.22USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$12.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
135,339
52-wk High
$13.41
52-wk Low
$4.29

Chart for

About

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR,... (more)

Overall

Beta: --
Market Cap(Mil.): $763.12
Shares Outstanding(Mil.): 93.52
Dividend: --
Yield (%): --

Financials

  ADAP.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.00 -- --
ROI: -32.06 1.58 14.38
ROE: -35.60 2.41 16.07

BRIEF-Adaptimmune Therapeutics Reports Quarterly Loss Per Ordinary Share Of $0.05

* ADAPTIMMUNE REPORTS FOURTH QUARTER / FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

15 Mar 2018

BRIEF-Adaptimmune Announces Responses In Second Solid Tumor Indication

* ADAPTIMMUNE ANNOUNCES RESPONSES IN SECOND SOLID TUMOR INDICATION WITH NY-ESO SPEAR T-CELLS

15 Mar 2018

BRIEF-Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK

* ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING

08 Jan 2018

BRIEF-Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells

* ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE

08 Jan 2018

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

* Adaptimmune reports third quarter 2017 financial results and business updates

02 Nov 2017

Earnings vs. Estimates